PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative

Overview

Journal J Pers Med

Date 2022 Dec 29

PMID 36579519

Authors

Liliana Ascione

Paola Zagami

Eleonora Nicolo

Edoardo Crimini

Giuseppe Curigliano

Carmen Criscitiello

Affiliations

Soon will be listed here.

Abstract

The phosphoinositide 3-kinase (PI3K) pathway plays a key role in cancer, influencing growth, proliferation, and survival of tumor cells. mutations are generally oncogenic and responsible for uncontrolled cellular growth. PI3K inhibitors (PI3Ki) can inhibit the PI3K/AKT/mTOR pathway, although burdened by not easily manageable toxicity. Among PI3Ki, alpelisib, a selective p110α inhibitor, is approved for the treatment of hormone receptor (HR)+/HER2- mutant metastatic breast cancer (BC) that has progressed to a first line endocrine therapy. mutations are also present in triple negative BC (TNBC) and HER2+ BC, although the role of PI3K inhibition is not well established in these subtypes. In this review, we go through the PI3K/AKT/mTOR pathway, describing most common mutations found in PI3K genes and how they can be detected. We describe the available biological and clinical evidence of mutations in breast cancers other than HR+/HER2-, summarizing clinical trials investigating PI3Ki in these subtypes.

Citing Articles

Beyond traditional biopsies: the emerging role of ctDNA and MRD on breast cancer diagnosis and treatment.

Sabit H, Attia M, Mohamed N, Taha P, Ahmed N, Osama S Discov Oncol. 2025; 16(1):271.

PMID: 40050490 PMC: 11885725. DOI: 10.1007/s12672-025-01940-6.

Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets.

Sirek T, Krol-Jatrega K, Borawski P, Zmarzly N, Boron D, Ossowski P Front Oncol. 2025; 14():1515387.

PMID: 39850811 PMC: 11754234. DOI: 10.3389/fonc.2024.1515387.

Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting.

Olsson E, Lindman H, Digkas E, Thurfjell V, Ali H, Kruger U Breast. 2025; 79:103874.

PMID: 39778370 PMC: 11761257. DOI: 10.1016/j.breast.2025.103874.

Spatial transcriptomics reveals substantial heterogeneity in triple-negative breast cancer with potential clinical implications.

Wang X, Venet D, Lifrange F, Larsimont D, Rediti M, Stenbeck L Nat Commun. 2024; 15(1):10232.

PMID: 39592577 PMC: 11599601. DOI: 10.1038/s41467-024-54145-w.

The PIK3CA gene and its pivotal role in tumor tropism of triple-negative breast cancer.

Mallick S, Duttaroy A, Dutta S Transl Oncol. 2024; 50:102140.

PMID: 39369580 PMC: 11491976. DOI: 10.1016/j.tranon.2024.102140.

References

Wallin J, Guan J, Prior W, Lee L, Berry L, Belmont L . GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res. 2012; 18(14):3901-11. DOI: 10.1158/1078-0432.CCR-11-2088. View

Kwon M . Predictive biomarkers for molecularly targeted therapies and immunotherapies in breast cancer. Arch Pharm Res. 2022; 45(9):597-617. DOI: 10.1007/s12272-022-01402-5. View

Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S . Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. 2012; 30(16):1989-95. DOI: 10.1200/JCO.2011.39.0823. View

Peng W, Chen J, Liu C, Malu S, Creasy C, Tetzlaff M . Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2015; 6(2):202-16. PMC: 4744499. DOI: 10.1158/2159-8290.CD-15-0283. View

Asghar U, Barr A, Cutts R, Beaney M, Babina I, Sampath D . Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer. Clin Cancer Res. 2017; 23(18):5561-5572. PMC: 6175044. DOI: 10.1158/1078-0432.CCR-17-0369. View

Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X . Genomic Alterations in -Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors. Cancer Res. 2021; 81(9):2470-2480. PMC: 8137641. DOI: 10.1158/0008-5472.CAN-20-3232. View

Castel P, Toska E, Engelman J, Scaltriti M . The present and future of PI3K inhibitors for cancer therapy. Nat Cancer. 2022; 2(6):587-597. PMC: 8809509. DOI: 10.1038/s43018-021-00218-4. View

Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z . Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res. 2005; 7(5):R609-16. PMC: 1242128. DOI: 10.1186/bcr1262. View

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

10.

Andre F, Hurvitz S, Fasolo A, Tseng L, Jerusalem G, Wilks S . Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol. 2016; 34(18):2115-24. DOI: 10.1200/JCO.2015.63.9161. View

11.

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E . PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol. 2016; 27(8):1519-25. PMC: 6279074. DOI: 10.1093/annonc/mdw197. View

12.

Goel S, Krop I . PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum. Ann Oncol. 2016; 27(8):1368-72. DOI: 10.1093/annonc/mdw246. View

13.

Mosele F, Stefanovska B, Lusque A, Tran Dien A, Garberis I, Droin N . Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020; 31(3):377-386. DOI: 10.1016/j.annonc.2019.11.006. View

14.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

15.

Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S . Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. Cancer Sci. 2015; 106(11):1582-9. PMC: 4714688. DOI: 10.1111/cas.12813. View

16.

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J . Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012; 13(2):135-44. DOI: 10.1016/S1470-2045(11)70397-7. View

17.

Zhang M, Jang H, Nussinov R . PI3K inhibitors: review and new strategies. Chem Sci. 2020; 11(23):5855-5865. PMC: 7472334. DOI: 10.1039/d0sc01676d. View

18.

Nunnery S, Mayer I . Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol. 2019; 30(Suppl_10):x21-x26. PMC: 6923786. DOI: 10.1093/annonc/mdz440. View

19.

Kalinsky K, Jacks L, Heguy A, Patil S, Drobnjak M, Bhanot U . PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009; 15(16):5049-59. DOI: 10.1158/1078-0432.CCR-09-0632. View

20.

Bianchini G, De Angelis C, Licata L, Gianni L . Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021; 19(2):91-113. DOI: 10.1038/s41571-021-00565-2. View